ETH Zurich Scientists Propose Protein Biomarker Discovery Strategy Guided by Cancer Genetics

Using the strategy, which is under development as a biomarker discovery platform at ETH Zurich spin-off firm ProteoMedix, the researchers have identified four protein biomarkers tied to prostate cancer.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.